We also summarize emerging prognostic biomarkers, such as immune infiltration patterns, circulating tumor DNA, and novel molecular markers including gasdermin D, which hold promise for refining patient prognosis and guiding personalized therapy. This evidence concerns the gene GSDMA and neoplasm.